These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Using the Electronic Medical Record to Correlate Kawasaki Disease Phenotypes With Clinical Outcomes. Jaggi P; Grcic M; Kovalchin J; Wilhelm CM; Yildirim-Toruner C; Texter K J Pediatric Infect Dis Soc; 2018 May; 7(2):119-123. PubMed ID: 28383697 [TBL] [Abstract][Full Text] [Related]
45. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Chen S; Dong Y; Yin Y; Krucoff MW Heart; 2013 Jan; 99(2):76-82. PubMed ID: 22869678 [TBL] [Abstract][Full Text] [Related]
46. Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study. Inamo Y; Saito K; Hasegawa M; Hayashi R; Nakamura T; Abe O; Ishikawa T; Yoshino Y; Hashimoto K; Fuchigami T BMC Pediatr; 2014 Jan; 14():27. PubMed ID: 24479564 [TBL] [Abstract][Full Text] [Related]
47. Association of Severity of Coronary Artery Aneurysms in Patients With Kawasaki Disease and Risk of Later Coronary Events. Miura M; Kobayashi T; Kaneko T; Ayusawa M; Fukazawa R; Fukushima N; Fuse S; Hamaoka K; Hirono K; Kato T; Mitani Y; Sato S; Shimoyama S; Shiono J; Suda K; Suzuki H; Maeda J; Waki K; ; Kato H; Saji T; Yamagishi H; Ozeki A; Tomotsune M; Yoshida M; Akazawa Y; Aso K; Doi S; Fukasawa Y; Furuno K; Hayabuchi Y; Hayashi M; Honda T; Horita N; Ikeda K; Ishii M; Iwashima S; Kamada M; Kaneko M; Katyama H; Kawamura Y; Kitagawa A; Komori A; Kuraishi K; Masuda H; Matsuda S; Matsuzaki S; Mii S; Miyamoto T; Moritou Y; Motoki N; Nagumo K; Nakamura T; Nishihara E; Nomura Y; Ogata S; Ohashi H; Okumura K; Omori D; Sano T; Suganuma E; Takahashi T; Takatsuki S; Takeda A; Terai M; Toyono M; Watanabe K; Watanabe M; Yamamoto M; Yamamura K JAMA Pediatr; 2018 May; 172(5):e180030. PubMed ID: 29507955 [TBL] [Abstract][Full Text] [Related]
48. Refractory Kawasaki disease: modified methylprednisolone regimen decreases coronary artery dilatation. Zhang M; Zheng Y; Li X; Yang S; Shi L; Li A; Liu Y Pediatr Res; 2022 May; 91(6):1542-1550. PubMed ID: 34021270 [TBL] [Abstract][Full Text] [Related]
49. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease. Chantasiriwan N; Silvilairat S; Makonkawkeyoon K; Pongprot Y; Sittiwangkul R Paediatr Int Child Health; 2018 Aug; 38(3):209-212. PubMed ID: 29768976 [TBL] [Abstract][Full Text] [Related]
50. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease. Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843 [TBL] [Abstract][Full Text] [Related]
51. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials. Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339 [TBL] [Abstract][Full Text] [Related]
52. The effects of early intravenous immunoglobulin therapy for Kawasaki disease: The 22nd nationwide survey in Japan. Kuwabara M; Yashiro M; Ae R; Yanagawa H; Nakamura Y Int J Cardiol; 2018 Oct; 269():334-338. PubMed ID: 30049499 [TBL] [Abstract][Full Text] [Related]
53. Corticosteroid administration for patients with coronary artery aneurysms after Kawasaki disease may be associated with impaired regression. Millar K; Manlhiot C; Yeung RS; Somji Z; McCrindle BW Int J Cardiol; 2012 Jan; 154(1):9-13. PubMed ID: 20851480 [TBL] [Abstract][Full Text] [Related]
54. High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more. Suzuki T; Michihata N; Yoshikawa T; Hata T; Matsui H; Fushimi K; Yasunaga H Eur J Pediatr; 2020 Dec; 179(12):1901-1907. PubMed ID: 32862279 [TBL] [Abstract][Full Text] [Related]
55. Kawasaki disease: 40 years after the original report. Gedalia A Curr Rheumatol Rep; 2007 Aug; 9(4):336-41. PubMed ID: 17688844 [TBL] [Abstract][Full Text] [Related]
58. Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India. Pilania RK; Jindal AK; Johnson N; Prithvi A; Vignesh P; Suri D; Rawat A; Gupta A; Singh S Rheumatology (Oxford); 2021 Jul; 60(7):3413-3419. PubMed ID: 33221920 [TBL] [Abstract][Full Text] [Related]
59. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin. Kibata T; Suzuki Y; Hasegawa S; Matsushige T; Kusuda T; Hoshide M; Takahashi K; Okada S; Wakiguchi H; Moriwake T; Uchida M; Ohbuchi N; Iwai T; Hasegawa M; Ichihara K; Yashiro M; Makino N; Nakamura Y; Ohga S Int J Cardiol; 2016 Jul; 214():209-15. PubMed ID: 27070994 [TBL] [Abstract][Full Text] [Related]
60. Treatment and Coronary Artery Aneurysm Formation in Kawasaki Disease: A Per-Day Risk Analysis. van Stijn D; Korbee JM; Netea SA; de Winter VC; Zwinderman KAH; Kuipers IM; Kuijpers TW J Pediatr; 2022 Apr; 243():167-172.e1. PubMed ID: 34968497 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]